SCHEMBL2805056

SCHEMBL2805056

Cc1cccc(S(=O)(=O)N2CCc3c(cnc4[nH]ncc34)C2)c1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 10/20 0.44
GRM5 P41594 1/20 0.43
AKR1C1 Q04828 1/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
POLB P06746 1/20 0.40
AKR1C2 P52895 1/20 0.39
PPARG P37231 1/20 0.39
PPARD Q03181 1/20 0.39
PPARA Q07869 1/20 0.39
HDAC1 Q13547 1/20 0.39
LMNA P02545 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
EPHX2 P34913 1/20 0.39
ATM Q13315 1/20 0.39
JAK2 O60674 1/20 0.39
JAK1 P23458 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2808596 0.88 MEN1 (0.45) AKR1C3AKR1C1MEN1KMT2APOLB
SCHEMBL2805055 0.88 AKR1C3 (0.44) AKR1C3AKR1C1MEN1KMT2APOLB
SCHEMBL2804811 0.87 PKM (0.44) POLB
SCHEMBL2804355 0.87 AKR1C3 (0.47) AKR1C3HDAC1LMNASMN1; SMN2
SCHEMBL2486484 0.87 MEN1 (0.51) AKR1C3AKR1C1MEN1KMT2APOLB
SCHEMBL2806316 0.85 AKR1C3 (0.46) AKR1C3AKR1C1MEN1KMT2APOLB
SCHEMBL2802461 0.85 KDM4E (0.46) PPARGPPARDPPARAHDAC1LMNA
SCHEMBL2802935 0.85 MAPT (0.41) AKR1C3MEN1KMT2APOLBAKR1C2
SCHEMBL12316149 0.84 KMT2A (0.41) AKR1C3MEN1KMT2APOLBAKR1C2
SCHEMBL2802794 0.84 SMN1; SMN2 (0.41) KMT2ALMNASMN1; SMN2EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS NQO1, IDH3B, IDH1 AKR1C3 1802/4885GRM5 1037/4885AKR1C1 1535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.